Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00323115 · ClinicalTrials.gov registry record · Phase 2
Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme
A Phase 2 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00323115 is a Phase 2 study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 11 participants.
The verdict
NCT00323115, a Phase 2 study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
Adult patients who have surgical resection of newly diagnosed glioblastoma multiforme will be treated with radiotherapy/chemotherapy followed by dendritic cell vaccine. Chemotherapy will be administered after three vaccinations for one year or until progression of disease.
Interventions
- DRUG Temozolomide
- BIOLOGICAL Dendritic Cell Vaccine
- PROCEDURE Radiotherapy
- BIOLOGICAL Autologous Dendritic Cell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2006-05 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00323115
The ClinicalTrials.gov registry entry for NCT00323115 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Temozolomide is the first listed.
NCT00323115 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00323115 about?
NCT00323115 is a clinical study titled "Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme". Adult patients who have surgical resection of newly diagnosed glioblastoma multiforme will be treated with radiotherapy/chemotherapy followed by dendritic cell vaccine. Chemotherapy will be administered after three vaccinations for one year or until progression of disease.
What is the current status of trial NCT00323115?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2006-05. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00323115?
The interventions under investigation include: Temozolomide (DRUG), Dendritic Cell Vaccine (BIOLOGICAL), Radiotherapy (PROCEDURE), Autologous Dendritic Cell (BIOLOGICAL).
Who is sponsoring clinical trial NCT00323115?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.